Novoviah

Novoviah Pharmaceuticals is a Brisbane-based biotechnology company founded in 2020, dedicated to pioneering ultrasensitive clinical tests for antigen-specific T cells. Their proprietary Novoleukin™ platform supports pharmaceutical clinical trials and researchers working across immune-mediated conditions — with applications initially validated in coeliac disease and expanding into autoimmune conditions, viral infections, and some cancers.